Resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer. By profiling the spectrum of outcomes arising from...

Researchers at Ulsan National Institute of Science and Technology in South Korea have developed a CRISPR-Cas9-based method to eliminate tumour cells....

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

At a Danish hospital, researchers have integrated CRISPR gene editing into a clinical scale workflow for immunotherapy. Gene editing releases a brake...

In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...

This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...